| Test Name: |
|
CA 27.29
|
|
|
|
|
|
|
| Test Code(s): |
|
CA2729 / X2729
|
|
|
|
|
|
|
| CPT Code(s): |
|
86300
|
|
|
|
|
|
|
| Methodology: |
|
Chemiluminescent Immunoassay
|
|
|
|
|
|
|
| Days Performed: |
|
Mon-Fri, dayshift.
|
|
|
|
|
|
|
| Turnaround Time: |
|
Routine: Next working day.
|
|
|
|
Specimen Requirements
|
|
|
|
| Specimen: |
|
Blood
|
|
|
|
|
|
|
| Collection Container: |
|
Preferred: Red cap with yellow ring (SST)
Also Acceptable:
Red top
|
|
|
|
|
|
|
| Collection Volume: |
|
Preferred: 1 mL
Pediatrics: 0.5 mL
|
|
|
|
|
|
|
| Sample Analyzed: |
|
Serum
|
|
|
|
|
|
|
| Volume Required: |
|
Preferred: 0.5 mL
Pediatrics: 0.15 mL
|
|
|
|
|
|
|
| Specimen Processing: |
|
Centrifuge. If a complete barrier has not formed, transfer cell-free serum to plastic vial. Refrigerate.
|
|
|
|
|
|
|
| Specimen Transport: |
|
Transport specimen to UWHC Core Laboratory (B4/220). Transport with coolant pack if coming from outreach location.
|
|
|
|
|
|
|
| Stability: |
|
Ambient: 8 hours
Refrigerated: 48 hours
Frozen: okay
|
|
|
|
Interpretation
|
|
|
|
|
Reference Interval:
|
|
0-39 U/mL
|
|
|
|
|
|
|
| Test Limitations: |
|
The Siemens ADVIA Centaur method is used. Results obtained with different assay methods or kits cannot be used interchangeably.
Results may be affected if patient has developed heterophilic antibodies due to exposure to animal based protein products.
|
|
|
|
|
|
|
| Additional Information: |
|
The CA 27.29 assay is intended for use as an aid in monitoring patients previously treated for Stage II or Stage III breast cancer. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. This test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment.
Patients with confirmed breast carcinoma frequently have levels of CA 27.29 within the range observed in healthy individuals. Additionally, elevated levels of CA 27.29 can be observed in patients with nonmalignant diseases.
|
